Year: 2025

Nasdaq CopenhagenEuronext DublinLondon Stock ExchangeDanish Financial Supervisory AuthorityOther stakeholders Date        17 November 2025 Share buyback programme – week 46 The share buyback programme runs in the period 2 June 2025 up to and including 30 January 2026, see company announcement of 2 June 2025. During the period the bank will thus buy back its own shares for a total of up to DKK 1,000 million under the programme, but to a maximum of 1,600,000 shares. The programme is implemented in compliance with EU Commission Regulation No. 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No. 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” regulation. The following transactions have been made under the programme:Date Number of shares Average purchase price (DKK) Total purchased under the...

Perspectives from Nxera’s major shareholders provide deeper insights into their investment views and confidence in the Company’s strategyTokyo, Japan and Cambridge and London, UK, 17 November 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces the release of two video interviews with its major shareholders, available on the Company’s official YouTube channel. Nxera invited its major shareholders to share their perspectives on the Company’s strategy, operations and investment appeal, offering valuable insights for all stakeholders, including shareholders and investors, to better understand Nxera’s business. In the first interview, conducted in July 2025, Nxera welcomed Mr. Yoshiharu Asai, a venture capitalist from JIC Venture Growth Investments Co., Ltd. (“JIC VGI”), part of the Japan Investment Corporation...

Euronext announces tender offer on existing EUR 2026 Bonds and intention to launch a new bonds issuance Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 17 November 2025 – Euronext N.V. (the Offeror) announces today an invitation to holders of its outstanding €600,000,000 0.125 per cent. Bonds due 2026 (ISIN: DK0030485271) (of which €600,000,000 in aggregate principal amount currently remains outstanding) (the Bonds) to tender any and all such Bonds for purchase by the Offeror for cash (such invitation, the Offer). The Offer is being made on the terms and subject to the conditions (including, but not limited to, the New Issue Condition (as defined below)) described in the tender offer memorandum dated 17 November 2025 (the Tender Offer Memorandum) prepared by the Offeror in connection with the Offer, and is subject to the offer...

NEW ADDITIONAL SHARE BUY-BACK OF EUR 1 BILLION Regulated Information Paris, 17 November 2025, 8:00 a.m. Societe Generale announces today a new exceptional capital distribution in the form of an additional EUR 1 billion share buy-back programme. The Board of Directors approved the launch of a new additional share buy-back programme, for cancellation purpose, of EUR 1 billion. Societe Generale obtained all necessary authorisations1, including from the ECB. These acquisitions of shares will be executed in compliance with the Market Abuse Regulation (MAR). Societe Generale will start to repurchase its shares on 19 November 2025 at the earliest. Press contacts:Jean-Baptiste Froville_+33 1 58 98 68 00_ jean-baptiste.froville@socgen.com Fanny Rouby_+33 1 57 29 11 12_ fanny.rouby@socgen.com Societe Generale Societe Generale is a top tier European...

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS CASCAIS, Portugal, Nov. 17, 2025 (GLOBE NEWSWIRE) — Pulsar Helium Inc. (AIM: PLSR, TSXV: PLSR, OTCQB: PSRHF) (“Pulsar” or the “Company”), a primary helium development company, is pleased to announce that Thomas Abraham-James, Pulsar’s CEO, and Dr. Peter Barry, the Company’s Scientific Helium-3 Advisor, will provide a live investor presentation via Investor Meet Company...

PRESS RELEASENovember 17, 2025JOSEP MARIA RECASENS APPOINTED CHIEF STRATEGY, PRODUCT & PROGRAM MANAGEMENT OFFICER Boulogne-Billancourt, France, November 17, 2025 – Renault Group announces the appointment of Josep Maria Recasens as Chief Strategy, Product & Program Management Officer (SPPM), effective immediately. This change is part of a drive to simplify the organisation in order to increase its agility and speed. Reporting to François Provost, CEO of Renault Group, and as a member of the Leadership Team, Josep Maria Recasens will be responsible for defining the strategy to maintain the Group’s positive momentum, guiding product choices for the coming years and coordinating the implementation to ensure the success of the future line-up. In addition to his new role, Recasens will remain CEO of the Iberian Peninsula countries....

Tokyo, Japan and Cambridge and London, UK, 17 November 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announced a focused restructuring designed to concentrate investment and resources on efficient platforms, programs and products with the greatest value creation potential. Alongside a focus on prioritized programs, Nxera intends to implement initiatives to reduce operating expenses to support Nxera’s 2030 vision of ≥JPY50 billion in net sales and an operating profit margin of ≥30%. Nxera will discuss plans for this focused restructuring at its R&D Day webcast to be held tomorrow – for details on how to register, please go to link. Key objectives of the restructuringR&D focus and program prioritization: Strategic emphasis on best-in-class opportunities where the biology of G protein-coupled receptor...

TME Pharma announces receipt of agreements in principle to extend certain bond agreements Berlin, Germany, November 17, 2025, 08.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, announced today that certain holders of the bonds issued in May and August, 2025 have agreed in principle to extend the maturity of the bonds for a one year period.  These bond holders, Diede van den Ouden (CEO) and 2 members of the Supervisory Board, hold 29% of the regular bonds issued in May and August 2025 for a total face value amount of €718,946. TME Pharma will also discuss with other lenders who participated in the May and August 2025 bond issuance to try to procure similar extensions of their debt. TME Pharma believes now may...